Abstract: The present invention provides cannabis lines, extracts and methods for the treatment of inflammatory skin disorders such as psoriasis, eczema, melanoma skin cancer, and others. The method includes generation of unique lines, whole plant extract preparation, treating human 3D skin tissues and disease models with extracts in amount sufficient to modulate gene expression in the skin tissues. The modulation of gene expression then results in a reduction of the disease state-associated changes or aspects thereof in the treated skin tissues.

Abstract: The present invention provides new unique cannabis lines, extracts and methods for their use in anti-inflammatory therapies and modalities. The method includes generation of unique lines, whole plant extract preparation, treating normal human 3D tissues with UV to induce inflammation, and then with extracts in amount sufficient to profoundly down-regulate inflammation and molecular pathways involved in rheumatoid arthritis (RA), irritable bowel disease (IBD) and other auto-inflammatory disorders. The modulation of these pathways is a key to treatment success in RA, IBD and the other auto-inflammatory disorders.

Abstract: The present disclosure relates to compositions, including, hydrogel compositions useful as analgesics including cannabinoids and menthol in a composition formulated to be administrable to a non-human animal rectally as a suppository. The menthol component can be a stabilized menthol composition comprising menthol and at least one menthol stabilizer compound including undecylenic acid methyl ester, undecylenic acid or a salt of undecylenic acid.

Abstract: Disclosed herein are natural product compositions for treating ADHD and related disorders.

Abstract: The present invention provides for methods of obtaining an extract of Cannabis plant material as well as subsequent processing of the extract to provide a concentrate of Cannabis. The present invention also provides for pharmaceutical dosage forms (e.g., oral thin films and transdermal patches) that include the concentrate (or extract) of Cannabis, as well as methods of medical treatment that include administering the pharmaceutical dosage forms.

Abstract: A Bone-Strengthening Pill (BSP) as a dietary supplement to improve blood circulation and strengthen bone and muscle is characterized in that it is made from the following raw materials: Angelica Sinensis, Pseudo-ginseng and Carthamus Tinctorius L. BSP has the following beneficial effects: promoting blood circulation, dredging microcirculatory disturbance, significantly improving the level of human health, improving blood running in bone tissue and muscle tissue, and preventing or repairing microscopic damage of bone, cartilage tissue and muscle tissue.

Abstract: This invention relates to plant extracts containing nutritionally beneficial or medicinally active compounds. Some of these extracts, or the purified compounds contained therein, may be used for the nutritional support, prevention, treatment, or possible cure of various metabolic and other diseases and disorders in human beings and animals, including type 1 and type 2 diabetes, by regulating insulin signaling. This regulatory effect may include modulations of the levels and/or activity of the Insulin Receptor (IR), the Insulin-like Growth Factor (IGF) Receptor, and/or the Insulin Receptor Substrate (IRS) proteins in cells and tissues in the body.

Abstract: The present application relates to a compositions and methods comprising or expressing a MOMO30 protein derived from Momordica balsamina. The MOMO30 protein is about 30 kDa in size, is stable after being autoclaved at 120° C. for 30 min, resists proteolytic cleavage by trypsin, exhibits mannose-sensitive binding HIV gp120, exhibits hemagglutinin and chitinase activity, is capable of activating and stimulating T cell proliferation, is capable of preventing infection by HIV-1 or alleviating symptoms in an HIV-1 infected patients and comprises the amino acid sequence of SEQ ID NO: 1. The MOMO30 protein and/or a nucleic acid encoding the same may be used in methods for preventing or treating viral infections by HIV and other enveloped viruses.

Abstract: In general, embodiments of the present invention provide antiviral essential oil compositions, and methods of making and using the same. Essential oil compositions can include one or more essential oils, such as thyme essential oil, oregano essential oil, and/or cinnamon essential, optionally in combination with one or more emulsifiers. Essential oil compositions can be in the form of an emulsion and have droplet sizes less than about 25 microns. The use of these compositions in organisms and systems provides beneficial antiviral effects, among others.

Abstract: The present invention provides Sarcopoterium spinosum (S. spinosum) extracts for use in preventing, treating and/or reducing the risk of developing fatty liver disease in a subject, compositions comprising the extracts, and methods for using them.

Abstract: Disclosed are compositions and methods for their use for cosmetic applications. The composition can include Schisandra chinensis fruit extract, Secale cereale (rye) seed extract, Centella asiatica meristem cell culture, Alpinia galangal leaf extract, dihydroxymethyl chromone, tripeptide-1, tetradecyl aminobutyroylvalylaminobutyric urea trifluoroacetate, Alteromonas ferment filtrate, Pisum sativum (pea) extract, or combinations thereof. An effective amount of the composition can be applied on skin to inhibit production of TNF-? production, tyrosinase, and/or elastase in skin, inhibit the Matrix Metalloproteinase Enzyme activity in skin, and/or promote the production of fibronectin, collagen, elastin, laminin, and/or hyaluronic acid in skin.

Abstract: Provided herein are methods of treatment of psychiatric disorders requiring treatment with an antipsychotic drug, such as schizophrenia or schizoaffective disorder, comprising administration of both the antipsychotic drug and a W. somnifera plant part, extract, chemical constituent(s) thereof, or a derivative thereof to treat symptoms of the psychiatric disorder. Treatment is typically continued for at least four weeks. A combination dosage form comprising both the antipsychotic drug and the W. somnifera plant part, extract, chemical constituent(s) thereof, or a derivative thereof in amounts effective to treat the psychiatric disorder.

Abstract: The invention relates to a composition for treatment and management of Dementia. The composition is a combination of herbs and bhasmas. It includes herbs such as Bacopa monnieri, Convolvulus pluricaulis, Mucuna pruriens, Nardostachys jatamansi, Rauwolfia serpentina, Withania somnifera, Acorus calamus, Sida cordifolia and Emblica officinalis. It further includes Shilajit, Rasa sindura and bhasmas. The composition is useful in treating Cognitive dysfunction, Dementia and other cognitive impairments associated with neuro-degenerative disorders. Further, the composition is also useful in restoring and improving cognitive function.

Abstract: A cream formulation or topical use made of a mixture of naturally occurring biologically active phytochemical compounds that possess a variety of beneficial animal and human health effects. An extract from an aqueous extraction process or other active ingredients could be used in the cream formulation. The present invention generally provides for the preparation of cream formulations containing active ingredients that contain individually, or in combination, an analgesic, natural product extracts, or a protein or proteins from the tripartite motif family of proteins (TRIM). The analgesic will provide mitigation of pain during the healing process.

Abstract: A composition comprising caffeoylshikimic acids, protocatechuic acid, hydroxytyrosol, hydroxybenzoic acid, caffeoylshikimic acids and their derivatives extracted from any part of oil palm including but not confined to the vegetation liquor of palm oil milling and palm oil mill effluent, and a method for use in the preparation of a composition containing caffeoylshikimic acids, protocatechuic acid, hydroxytyrosol, hydroxybenzoic acid, caffeoylshikimic acids and their derivatives.

Abstract: Composition for the treatment and management of Polycystic ovarian syndrome and method of preparation thereof are disclosed herein. The disclosed Herbal composition includes herbs and minerals which facilitate in treating PCOS and PCOS associated symptoms. The composition comprises Saraca indica, Symplocos racemosa, Boerhavia diffusa, Tinospora cordifolia, Terminalia arjuna, Saccharum officinarum and Commiphora mukul, or extracts thereof; Shilajit; and bhasmas. The disclosed composition may also be instrumental in improving general reproductive health of an individual.

Abstract: Disclosed are antimicrobial peptides capable of inhibiting and killing multiple drug-resistant bacteria, including XH-12C, XH-12B and XH-12A. The application further provides uses of the antimicrobial peptides in the preparation of a drug for inhibiting and/or killing fungi, Gram-positive bacteria, Gram-negative bacteria and drug-resistant bacteria and in the manufacture of medical carriers.

Abstract: Disclosed are antimicrobial peptides capable of inhibiting and killing multiple drug-resistant bacteria, including XH-12C, XH-12B and XH-12A. The application further provides uses of the antimicrobial peptides in the preparation of a drug for inhibiting and/or killing fungi, Gram-positive bacteria, Gram-negative bacteria and drug-resistant bacteria and in the manufacture of medical carriers.

Abstract: The invention provides a combination comprising a compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable derivatives or prodrugs thereof and a polymyxin selected from polymyxin E and polymyxin B or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment of microbial infections.

Abstract: Provided herein are, inter alia, methods for treating rhinosinusitis with P-glycoprotein inhibitors. A subject having rhinosinusitis is identified and then treated by administration to the subject an effective amount of a P-gp inhibitor. The subject having rhinosinusitis can be identified by one of skill in the art based on known methods, e.g., based on detection of the presence of symptoms, by endoscopy, or by computed tomography. The efficacy of the treatment can be monitored by methods known in the art, e.g., by monitoring symptoms, by endoscopy or computed tomography. The P-glycoprotein inhibitor can be delivered to the subject's nasal passage and sinuses by an inhalation device, by flushing, by spraying, or by an eluting implant surgically placed in the subject's nasal passage or sinuses. The P-glycoprotein inhibitor can also be administered in combination with one or both of a corticosteroid and an antibiotic.

Abstract: The present invention relates to compositions and methods for treating autoimmune, microbial, metabolic, neoplastic, and posttraumatic diseases mediated by inflammation in a subject. Compositions and methods including at least one importin beta-selective nuclear transport modifier (NTM) and/or at least one importin alpha-selective NTM, and/or at least one importin alpha-specific NTM, and/or at least one inhibitor of importin alpha and importin beta complex formation may be administered to a subject to modulate the transport of transcription factors, mediated by nuclear import adaptors, into the nucleus of a cell resulting in a decrease or abrogation of inflammation.

Abstract: Compositions and methods for reducing the growth of and/or preventing the formation of a microbial biofilm are disclosed. The composition comprises an antimicrobial SMR peptide comprising an HIV-1 SMRwt peptide and a cell penetrating peptide (CPP) domain. In some embodiments, the composition further comprises one or more other antimicrobial peptides (AMPs), antibiotics, matrix-inhibiting compounds, matrix-disaggregating compounds, quorum sensing inhibitors, or a combination thereof. In other embodiments, the compositions are used for impregnating or coating an article and/or material surface with the composition to render it less prone to microbial infections.

Abstract: Methods, compositions and kits for regulating complement activity or treating a complement activity disorder in a subject using soluble, membrane-independent CD59 protein, methods of assaying human macular degeneration (MD), and methods and kits for assaying potential therapeutic agents for treatment of human MD are provided herein.

Abstract: The present invention relates to a CD24 protein for treating immune-related adverse events (irAEs) associated with cancer immunotherapy. Provided herein is a method of treating, mitigating, minimizing, or preventing immunerelated adverse events (irAEs) associated with a cancer immunotherapy by administering a CD24 protein to a subject in need thereof. The irAE may be diarrhea or another gastrointestinal disorder, pure red cell aplasia, microcytic anemia, lupus, autoimmune nephritism, autoimmune hepatitis, pneumonitis, myocarditis, pericarditis, endocrinopathy, Addison's disease, hypogonadism, Sjogren's syndrome, or type I diabetes. The CCD24 protein may comprise a mature human CD24 or a variant thereof.

Abstract: The present invention relates to improved phosphopeptide stabilised amorphous calcium phosphate and/or amorphous calcium fluoride phosphate complexes and compositions containing those complexes. Methods of making the complexes of the invention and of treatment dental hypersensitivity are also provided. In one embodiment, the invention provides a stannous-associated phosphopeptide (PP) stabilized amorphous calcium phosphate (ACP) or amorphous calcium fluoride phosphate (ACFP) complex having a stannous ion content of equal to, or greater than, 1 mole of stannous per mole of PP but less than 4 moles of stannous per mole of PP.

Abstract: Treatment of chronic neurodegenerative diseases such as multiple sclerosis (MS) remains a major challenge. Here we genetically engineer neural stem cells (NSCs) to produce a triply therapeutic cocktail comprising IL-10, NT-3, and LINGO-1-Fc, thus simultaneously targeting all mechanisms underlie chronicity of MS in the central nervous system (CNS): persistent inflammation, loss of trophic support for oligodendrocytes and neurons, and accumulation of neuroregeneration inhibitors. After transplantation, NSCs migrated into the CNS inflamed foci and delivered these therapeutic molecules in situ. NSCs transduced with one, two, or none of these molecules had no or limited effect when injected at the chronic stage of experimental autoimmune encephalomyelitis; cocktail -producing NSCs, in contrast, mediated the most effective recovery through inducing M2 macrophages/microglia, reducing astrogliosis, and promoting axonal integrity and endogenous oligodendrocyte/neuron differentiation.

Abstract: The present invention provides methods for treating hair loss, treating, inhibiting, or suppressing a degenerative skin disorder, treating androgenetic alopecia (AGA), generating new hair follicles (HF), and increasing the size of existing HF. The methods comprise epidermal disruption or administration of wnt, a fibroblast growth factor-9 polypeptide or another compound that upregulates sonic hedgehog gene signaling.

Abstract: Provided herein are methods of modulating bile acid homeostasis or treating a bile-acid related or associated disorder, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), in combination with agents effective in modulating bile acid homeostasis or treating a bile-acid related or associated disorder.

Abstract: Provided herein are pharmaceutical compositions, formulations and dosage forms comprising variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics). Methods of using the pharmaceutical compositions, formulations and dosage forms are also provided herein.

Abstract: The invention relates to MIC-1 compounds for use in the prevention and/or treatment of obesity, wherein the MIC-1 compounds is administered simultaneously, separately or sequentially with a GLP-1 compound.

Abstract: The present invention provides combinations of (a) an immunoconjugate comprising a first antibody engineered to have reduced effector function and an effector moiety, and (b) a second antibody engineered to have increased effector function, for use in treating a disease in an individual in need thereof. Further provided are pharmaceutical compositions comprising the combinations, and methods of using them.

Abstract: Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility in patients having high AMH and low bodyweight.

Abstract: Provided herein are pharmaceutical compositions containing a therapeutic agent, an alkylglycoside, and pharmaceutically acceptable excipients and use of such compositions in the treatment of various conditions.

Abstract: The present invention relates to a recombinant polypeptide comprising a truncated von Willebrand Factor (VWF) capable of binding to blood coagulation Factor VIII (FVIII) for use in reducing the immunogenicity of Factor VIII (FVIII) wherein said recombinant polypeptide and a blood coagulation Factor VIII (FVIII) protein are co-administered to a subject suffering from a 10 blood coagulation disorder. The invention further relates to pharmaceutical compositions and kits for said use.

Abstract: The present invention in particular relates to the field of micro- and nanoparticles, more in particular to coated nanoparticles. The coatings of the present invention in particular comprise surfactant protein B (SP-B) and one or more lipids. The invention further relates to such coated particles and compositions comprising them for use as a medicament, in particular for use in the treatment of various disorders. Furthermore, the invention provides the use of the compositions of the current invention for delivering one or more agents, such as small interfacing RNA (siRNA) molecules, to the target tissue or cells.

Abstract: Disclosed herein are chimeric antigen receptor effector cells (CAR-ECs) and CAR-EC switches. The switchable CAR-ECs are generally T cells. The one or more chimeric antigen receptors may recognize a peptidic antigen on the CAR-EC switch. The CAR-ECs and switches may be used for the treatment of a condition in a subject in need thereof.

Abstract: Disclosed are compositions related to synthetic PD-1 peptides, chimeric PD-1 peptides, anti-PD-1 antibodies and methods of treating cancers, autoimmune diseases, and Alzheimer's disease using said peptides or antibodies.

Abstract: The present invention relates to a process for preparing an immunotherapeutic yeast, said immunotherapeutic yeast expressing one or more tumor antigen(s) at its wall, and also to immunotherapeutic yeasts capable of being obtained by carrying out the process of the invention.

Abstract: Disclosed herein are alphavirus vectors that include neoantigen-encoding nucleic acid sequences derived from a tumor of a subject. Also disclosed are nucleotides, cells, and methods associated with the vectors including their use as vaccines.

Abstract: The present invention discloses a rabbit coccidiosis vaccine and application thereof, the vaccine comprises 100 to 800 Eimeria media/dose, 200 to 1600 Eimeria magna/dose, and 100 to 800 Eimeria intestinalis/dose. The composition of the vaccine possesses the characteristics as scientific reasonable, low cost, no drug residue or drug resistance or environmental pollution would occur, good immunogenicity and safe to use. After oral immunization in rabbits, it may effectively resist the infections of 1×105 Eimeria media, 5×104 Eimeria magna and 3×103 Eimeria intestinalis. It also may be used to prepare a pharmaceutical preparation against rabbit coccidiosis.

Abstract: The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.

Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and/or pneumococcal diseases caused by S. pneumoniae.

Abstract: The present invention relates to immunogenic compositions, such as vaccines, comprising immunogenic polypeptides from Haemophilus influenzae and Moraxella catarrhalis, for use in methods of boosting an immune response and methods of treatment using same. More particularly, the invention relates to use of such immunogenic compositions in methods of treating or preventing exacerbation of chronic obstructive pulmonary disease.

Abstract: The present invention discloses a live attenuated strain of Zika virus (ZIKV) having a deletion in the 3? untranslated region (3?UTR) of the viral genome, which may affect viral RNA synthesis and sensitivity to type I interferon inhibition, but may not affect viral RNA translation. The present invention also discloses the use of these live attenuated ZIKV strains in the preparation of ZIKV vaccines and for providing immunoprotection against ZIKV infection and congenital ZIKV syndrome, particularly in pregnant females.

Abstract: Described herein are improved purification methods for virus vaccines and compositions. Also described are Zika, Chikungunya, dengue and yellow fever vaccines and methods of producing and administering said vaccines to subjects in need thereof.

Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided.

Abstract: The present invention relates to methods and compositions for stimulating an immune response. In particular, the present invention relates to immunostimulatory RNA molecules comprising sequences derived from an Influenza A virus nucleoprotein-encoding RNA molecule that act as adjuvants and/or immunostimulatory agents to enhance host immune responses.

Abstract: Methods of inducing a safe immune response against respiratory syncytial virus (RSV) in a human subject in need thereof, including administering to the subject a composition including recombinant adenovirus including a nucleic acid encoding an RSV Fusion (F) protein including the amino acid sequence of SEQ ID NO: 1, and a pharmaceutically acceptable carrier, in a total dose of from about 1×1010 to about 2×1011 viral particles (vp), are described.

Abstract: The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

Abstract: The present application relates to the field of human immunology, in particular, a herpes simplex virus (HSV) vaccine. The subunit vaccine composition comprises isolated surface glycoproteins from herpes simplex viruses, fusion proteins or fragments thereof mixed in varied combination with a nanoemulsion, which is a potent immune enhancer.